Marshall Wace
CPRX

Marshall Wace’s Catalyst Pharmaceutical CPRX Stock Holding History

Marshall Wace’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.7M Buy
911,700
+709,885
+352% +$21M 0.02% 574
2026
Q1 		$5M Buy
201,815
+188,588
+1,426% +$4.49M 0.01% 1306
2025
Q4 		$309K Sell
13,227
-10,876
-45% -$242K ﹤0.01% 2441
2025
Q3 		$475K Sell
24,103
-116,720
-83% -$2.4M ﹤0.01% 2245
2025
Q2 		$3.06M Buy
+140,823
New +$3.32M ﹤0.01% 1366
2025
Q1 		– Sell
-253,637
Closed -$5.29M – 2691
2024
Q4 		$5.29M Sell
253,637
-607,297
-71% -$13M 0.01% 1035
2024
Q3 		$17.1M Sell
860,934
-358,603
-29% -$6.65M 0.02% 564
2024
Q2 		$18.9M Sell
1,219,537
-464,414
-28% -$7.23M 0.03% 526
2024
Q1 		$26.8M Buy
+1,683,951
New +$25.4M 0.04% 418
2023
Q4 		– Sell
-73,991
Closed -$865K – 2230
2023
Q3 		$865K Sell
73,991
-120,012
-62% -$1.61M ﹤0.01% 1548
2023
Q2 		$2.61M Buy
+194,003
New +$2.79M 0.01% 1282
2022
Q1 		– Sell
-200,308
Closed -$1.36M – 3438
2021
Q4 		$1.36M Buy
+200,308
New +$1.32M ﹤0.01% 2299
2021
Q2 		– Sell
-103,332
Closed -$476K – 2705
2021
Q1 		$476K Sell
103,332
-38,466
-27% -$153K ﹤0.01% 1965
2020
Q4 		$474K Sell
141,798
-155,182
-52% -$521K ﹤0.01% 1477
2020
Q3 		$882K Sell
296,980
-32,450
-10% -$127K 0.01% 1066
2020
Q2 		$1.52M Sell
329,430
-775,996
-70% -$3.49M 0.01% 881
2020
Q1 		$4.26M Sell
1,105,426
-462,138
-29% -$1.9M 0.04% 424
2019
Q4 		$5.88M Buy
+1,567,564
New +$7.33M 0.04% 477

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's CPRX Position: Q2 2026 in Review

Marshall Wace increased its Catalyst Pharmaceutical (CPRX) stake by 352% in Q2 2026, buying an estimated $21M and bringing the position to 911,700 shares worth $28.7M. The position accounts for 0.02% of the portfolio, ranked #574.

Marshall Wace first reported a position in CPRX in Q4 2019 and has held it in 18 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Marshall Wace held 911,700 shares of Catalyst Pharmaceutical worth $28.7M as of Q2 2026.
  • Marshall Wace bought 709,885 Catalyst Pharmaceutical shares in Q2 2026, an estimated $21M.
  • Catalyst Pharmaceutical made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #574 holding.
  • Marshall Wace first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 18 quarters since.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.